Collegium Pharmaceutical Deal History & Licensing Activity
Collegium Pharmaceutical is a life sciences. Over the past three years, Collegium Pharmaceutical has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Neurology
Collegium Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Collegium Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Azstarys | Corium Therapeutics | Small Molecules | Approved | acquisition | Mar 2026 |
Collegium Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Collegium Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Collegium Pharmaceutical's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Collegium Pharmaceutical Licensing & Deal Activity
Collegium Pharmaceutical is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Collegium Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Collegium Pharmaceutical include Neurology (2 deals and trials). In terms of modality, Collegium Pharmaceutical has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Collegium Pharmaceutical and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Collegium Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.